Ceribell Q4 revenue $18.5M (+41% YoY); FY2024 revenue $65.4M (+45%); guides FY2025 $81-85M

Ceribell, Inc.

2024-FY EPS reported -$3.39 revenue$65,444,000

Q4 revenue $18.5M (+41% YoY); product $14.1M, subscription $4.4M; gross margin 88%.
FY2024 revenue $65.4M (+45%); net loss $40.5M ($3.39/share) vs $29.5M ($5.56/share) in 2023.
Cash and equivalents $194.4M at Dec 31, 2024; active accounts 529; over 200,000 patients treated.
FY2025 revenue guidance $81-85M, representing 24-30% growth over FY2024.
Submitted 510(k) for pediatric Clarity algorithm; Sean Manni promoted to Chief Revenue Officer.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.